Financials

Discussions Technicals Seasonals

461030 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

IMBdx, Inc. engages in the development of liquid biopsy tests for cancer diagnosis. It focuses on the following business areas: diagnosis and treatment of advanced cancer, early detection of recurrence after surgery, and early cancer diagnosis. Its products include AlphaLiquid, CancerDetect, and CancerFind. The company was founded by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018 and is headquartered in Seoul, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

461030 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company